Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19
Ammar Ali Almarzooq
doi: https://doi.org/10.1101/2021.04.24.21256047
Ammar Ali Almarzooq
1Galore Consultancy, Flat 12, Building 144, Road 336, Block 314, Manama, Bahrain
Article usage
Posted April 27, 2021.
Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19
Ammar Ali Almarzooq
medRxiv 2021.04.24.21256047; doi: https://doi.org/10.1101/2021.04.24.21256047
Subject Area
Subject Areas
- Addiction Medicine (403)
- Allergy and Immunology (712)
- Anesthesia (207)
- Cardiovascular Medicine (2969)
- Dermatology (253)
- Emergency Medicine (445)
- Epidemiology (12804)
- Forensic Medicine (12)
- Gastroenterology (830)
- Genetic and Genomic Medicine (4621)
- Geriatric Medicine (423)
- Health Economics (732)
- Health Informatics (2941)
- Health Policy (1073)
- Hematology (393)
- HIV/AIDS (932)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (475)
- Neurology (4405)
- Nursing (238)
- Nutrition (649)
- Oncology (2294)
- Ophthalmology (651)
- Orthopedics (260)
- Otolaryngology (327)
- Pain Medicine (281)
- Palliative Medicine (84)
- Pathology (502)
- Pediatrics (1199)
- Primary Care Research (502)
- Public and Global Health (7004)
- Radiology and Imaging (1544)
- Respiratory Medicine (921)
- Rheumatology (444)
- Sports Medicine (386)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)